Title Category Credit Event date Cost
Posttransplant Diagnostics: Utilizing Biomarkers and Genomics to Optimize Immunosuppression and Reduce Complications
  • Disease Management
  • Transplantation
  • ACPE - Pharmacists
  • ACPE - Pharmacy Technicians
  • AMA - Physicians
  • ANCC - Nurses
  • APA - Psychologists
  • Attendance - General Attendance
  • CCMC - General - Case Managers
  • CDR - Dietitians
  • ASWB - Social Workers
$0.00 In this activity, participants will review conventional rejection-monitoring parameters and will identify current and emerging acute-rejection biomarkers. A closer look at data — regarding such biomarkers as donor-derived cell-free DNA, gene expression profiles, mRNA transcripts, immune effector pathway molecules, cell subsets and chemokines — will provide clarity about their predictive accuracy and value in rejection monitoring, as well as their ability to improve outcomes through rapid identification of transplant-organ dysfunction.
Updates on Xenotransplantation and the Artificial Kidney
  • Disease Management
  • Transplantation
  • ACPE - Pharmacists
  • ACPE - Pharmacy Technicians
  • AMA - Physicians
  • ANCC - Nurses
  • APA - Psychologists
  • Attendance - General Attendance
  • CCMC - General - Case Managers
  • CDR - Dietitians
  • ASWB - Social Workers
$0.00 Join this activity to discuss how technology to treat end-stage kidney failure has advanced in recent years, including a review of clinical trials of portable devices and implantable xenotransplants, and what the future holds for the next phase of investigation into the artificial kidney and xenotransplant.
Selecting Appropriate Treatments Based on Geriatric and Fragility Assessments
  • Disease Management
  • Oncology
  • Older Adults
  • Transplantation
  • ACPE - Pharmacists
  • ACPE - Pharmacy Technicians
  • AMA - Physicians
  • ANCC - Nurses
  • APA - Psychologists
  • Attendance - General Attendance
  • CCMC - General - Case Managers
  • CDR - Dietitians
  • ASWB - Social Workers
$0.00 This activity will provide an overview of geriatric and frailty assessment tools that can assist in guiding cancer- and transplant-related decision making through the risk stratification of older individuals before therapy is initiated. Data surrounding the relationship among increased age, geriatric- and frailty-assessment results, and disease outcomes will also be explored. Key considerations in how to best incorporate these sometimes time-intensive assessments into practice will be outlined, along with discussion of how interprofessional collaboration among members of the health care team in the creation of care plans can facilitate quality care.
Social Determinants of Health in Cancer Care
  • Disease Management
  • Health Equity
  • Oncology
  • ACPE - Pharmacists
  • ACPE - Pharmacy Technicians
  • AMA - Physicians
  • ANCC - Nurses
  • APA - Psychologists
  • Attendance - General Attendance
  • CCMC - General - Case Managers
  • CDR - Dietitians
  • ASWB - Social Workers
$0.00 This activity will review the impact of poorer SDOH status on cancer care, disease progression, outcomes, access to treatment and many other aspects. It will also present care models, strategies and resources to help health care professionals best confront the challenges faced by many individuals with cancer.
Implications for Transplantation in Acute-on-Chronic Liver Failure: Determining a Course of Action
  • Disease Management
  • Transplantation
  • ACPE - Pharmacists
  • ACPE - Pharmacy Technicians
  • AMA - Physicians
  • ANCC - Nurses
  • APA - Psychologists
  • Attendance - General Attendance
  • CCMC - General - Case Managers
  • CDR - Dietitians
  • ASWB - Social Workers
$0.00 This activity will help participants to better determine the role and optimal timing of liver transplant in ACLF. It will review precipitators of ACLF associated with poorer outcomes, including bacterial infections and hepatitis B virus, and will explore posttransplant outcomes and predictors. The accuracy of current scoring systems for assessing the severity of disease and predicting survival will be discussed, including the Model for End-stage Liver Disease (MELD) score and the Chronic Liver Failure Consortium Organ Failure (CLIF-C OF) score.
Normothermic Regional Perfusion
  • Disease Management
  • Transplantation
  • ACPE - Pharmacists
  • ACPE - Pharmacy Technicians
  • AMA - Physicians
  • ANCC - Nurses
  • APA - Psychologists
  • Attendance - General Attendance
  • CCMC - General - Case Managers
  • CDR - Dietitians
  • ASWB - Social Workers
$0.00 This activity will discuss the opportunities presented by NRP to increase the availability of donor organs and allow for extended patient survival time until transplant. The principles of NRP, effects on graft survival, potential complications, and ethical and legal concerns will be reviewed.
Psychosocial Considerations in Post-Hematopoietic Stem Cell Transplantation
  • Behavioral health
  • Disease Management
  • Oncology
  • ACPE - Pharmacists
  • ACPE - Pharmacy Technicians
  • AMA - Physicians
  • ANCC - Nurses
  • APA - Psychologists
  • Attendance - General Attendance
  • CCMC - General - Case Managers
  • CDR - Dietitians
  • ASWB - Social Workers
$0.00 This activity will discuss the current approach for screening and management of these complications and will review data regarding the negative associations among psychological distress, health outcomes, successful HSCT, and increased mortality. Barriers in the delivery of psychosocial care and care models to address these issues will also be outlined.
A Closer Look at Novel Treatment Therapies for Acute Myeloid Leukemia
  • Disease Management
  • Oncology
  • ACPE - Pharmacists
  • ACPE - Pharmacy Technicians
  • AMA - Physicians
  • ANCC - Nurses
  • APA - Psychologists
  • Attendance - General Attendance
  • CCMC - General - Case Managers
  • CDR - Dietitians
  • ASWB - Social Workers
$0.00 This activity will discuss these novel agents’ indications, risks, and benefits and will address which patient populations are most likely to benefit from particular agents. In addition, early-phase clinical trials and emerging therapies will be explored.
Advances in Gene Therapy for Sickle Cell Disease and Thalassemia
  • Disease Management
  • Oncology
  • ACPE - Pharmacists
  • ACPE - Pharmacy Technicians
  • AMA - Physicians
  • ANCC - Nurses
  • APA - Psychologists
  • Attendance - General Attendance
  • CCMC - General - Case Managers
  • CDR - Dietitians
  • ASWB - Social Workers
$0.00 This session will examine the genetic approaches being explored for these diseases, such as the introduction of a corrected or modified β-globin gene and gene-sequence editing. It will also explore the genetic modalities utilized, such as genome-editing technologies including the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene-editing system and lentiviral vectors. The safety, efficacy and challenges associated with these therapies will also be outlined.
Emerging Applications of CAR T-cell Therapy in Cancer
  • Disease Management
  • Oncology
  • ACPE - Pharmacists
  • ACPE - Pharmacy Technicians
  • AMA - Physicians
  • ANCC - Nurses
  • APA - Psychologists
  • Attendance - General Attendance
  • CCMC - General - Case Managers
  • CDR - Dietitians
  • ASWB - Social Workers
$0.00 This activity will explore the most recent advances of this rapidly evolving therapy, including current data on its efficacy, limitations and challenges in the treatment of multiple myeloma and solid tumors. It will provide an overview of currently existing guidelines for CAR T-cell therapy and will describe best practices in determining individuals’ eligibility for this type of therapy, including factors that may affect treatment efficacy and outcomes.

Pages